Acadia Reports Third-Quarter 2026 Financial Results
Acadia reported third-quarter revenue of $342 million, citing continued commercial momentum across DAYBUE and NUPLAZID.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the third quarter ended September 30, 2026.“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chi…